Skip to main content
OpenTrials
Completed

NCT Number: NCT00941304

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

The purpose of this study is to assess the activity of buprenorphine hydrochloride (HCl) buccal film in the treatment of dental pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Premier Research Group Limited, Austin, Texas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • extraction of 2 or more third molars, at least 1 of which must be fully or partially impacted in mandibular bone
  • males or non-pregnant females, aged 18 to 45 years
  • good general health and capable of providing informed consent

Exclusion criteria

  • history of substance abuse or dependence
  • positive urine toxicology screen or alcohol breath test
  • history of hypersensitivity to or allergy to any study drug
  • donation of blood within prior 30 days
  • use of analgesics, caffeine, sedatives, antidepressants, anticoagulant or antiplatelet agents within 24 hours

Treatment and study plan

Oxycodone

Drug

Single-dose of over-encapsulated oral 5-mg oxycodone capsule

Other names: Oxycodone capsule

buprenorphine

Drug

Single-dose of buprenorphine HCl buccal film

Other names: BEMA Buprenorphine, BELBUCA, Buprenorphine HCl buccal film, Buprenorphine HCl buccal soluble film

Placebo Film

Drug

Single-dose of placebo buccal film

Other names: Placebo, Placebo buccal film, BEMA placebo

Placebo capsule

Drug

Single-dose of oral placebo capsule

Other names: Placebo, Oxycodone placebo

Primary outcomes

  1. Sum of Pain Intensity Difference From Baseline to 8 Hours

    Time frame: Baseline, 8 hours

    Time-weighted sum of pain intensity difference from baseline to 8 hours (SPID-8) where total score ranges from -80 (worst) to 80 (best) and a higher value indicates greater pain relief. Pain intensity was recorded using an 11-point numeric rating scale (NRS), where 0=none and 10=worst pain imaginable, in response to "What is your pain level at this time?"

Secondary outcomes

  1. Total Pain Relief Over 8 Hours

    Time frame: 8 hours

    Time-weighted sum of total pain relief over 8 hours (TOPAR-8) where total score ranges from 0 (worst) to 32 (best) and higher values indicate greater pain relief. Pain relief (PAR) was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to "How much relief have you had from your starting pain?"

  2. Sum of Pain Relief and Intensity Differences Over 8 Hours

    Time frame: 8 hours

    Time-weighted sum of PAR and pain intensity difference (PID) over 8 hours (SPRID-8) where total score ranges from -80 (worst) to 112 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to "How much relief have you had from your starting pain?" PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to "What is your pain level at this time?"

  3. Sum of Pain Relief and Intensity Differences Over 2 Hours

    Time frame: 2 hours

    Time-weighted sum of PAR and PID over 2 hours (SPRID-2) where total score ranges from 0 (worst) to 8 (best) and higher values indicate greater pain relief. PAR was recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to "How much relief have you had from your starting pain?" PID determined as the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to "What is your pain level at this time?"

  4. Peak Pain Intensity Difference

    Time frame: 24 hours

    The maximum PID at any time following dosing determined from the change from baseline pain intensity assessment. Pain intensity was recorded using an 11-point NRS, where 0=none and 10=worst pain imaginable, in response to "What is your pain level at this time?"

  5. Peak Pain Relief

    Time frame: 24 hours

    Maximum pain relief (PAR) at any time following dosing, recorded using a 5-point categorical rating scale, where 0=none, 1=a little, 2=some, 3=a lot, and 4=complete, in response to "How much relief have you had from your starting pain?"

  6. Onset of Analgesia

    Time frame: 8 hours

    Time to onset of analgesia defined as median time to perceptible pain relief if confirmed by experiencing meaningful pain relief from time of study drug administration.

  7. Duration of Analgesia

    Time frame: 24 hours

    Duration of analgesia was the median time to use of rescue medication; earliest concomitant medication start time for medications identified as rescue medications from time of study drug administration.

  8. Percentage of Participants Reporting a Global Rating of Study Drug as "Excellent"

    Time frame: 8 hours and 24 hours

    Subjects rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to "Overall, how would you rate the study medication you received for pain?"

  9. Percentage of Participants With "Excellent" Investigator Global Rating of Study Drug

    Time frame: 24 hours

    Investigators rated the global effectiveness of study drug as poor, fair, good, or excellent, in response to "Overall, how would you rate the study medication for this subject?"

  10. Change From Baseline in Cognitive Assessment Using CNS-VS

    Time frame: Baseline (screening), 2 hours 15 minutes postdose

    Cognition assessed using computer-based CNS Vital Signs® neurocognitive function test (CNS-VS), including symbol digit coding, Stroop test, and shifting attention test to measure cognitive flexibility, executive functioning, processing speed, and reaction time(*). Scores are computed from raw score calculations using the data values of individual subtests. An asterisk denotes that "lower score is better", otherwise higher scores are better.

Sponsors and collaborators

Lead sponsor

BioDelivery Sciences International

Industry

Registry information

Official study title

A Double-Blind, Double-Dummy, Placebo- and Active Controlled Evaluation of the Efficacy, Safety and Tolerability of Buprenorphine HCl Buccal Film in the Treatment of Pain Associated With Third Molar Extraction

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Jul 17, 2009
Registry last updated
Feb 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.